We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+34.21%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$8.57B
AUM Growth
+$1.33B
Cap. Flow
+$552M
Cap. Flow %
6.44%
Top 10 Hldgs %
58.85%
Holding
53
New
11
Increased
15
Reduced
3
Closed
7

Top Buys

Rank Stock Value
1
ARWR icon
Arrowhead Research
ARWR
+$238M
2
VERA icon
Vera Therapeutics
VERA
+$188M
3
ALPN
Alpine Immune Sciences Inc
ALPN
+$170M
4
VKTX icon
Viking Therapeutics
VKTX
+$160M
5
MGNX icon
MacroGenics
MGNX
+$93M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$287M
2
CBAY
Cymabay Therapeutics
CBAY
+$262M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$135M
4
GPCR icon
Structure Therapeutics
GPCR
+$95.1M
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$39.6M

Sector Composition

Rank Sector Weight
1 Healthcare 94.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRTX
51
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-125,000
Closed -$39.6M
IMGN
52
DELISTED
Immunogen Inc
IMGN
– –
-875,000
Closed -$25.9M
MRTX
53
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-4,886,840
Closed -$287M
1 2
3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Avoro Capital Advisors's Q1 2024 Portfolio in Review

As of Q1 2024, Avoro Capital Advisors held 53 positions worth $8.57B, up 18% from $7.24B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Avoro Capital Advisors deployed $552M of net new capital in Q1 2024, opening 11 new positions and adding to 15 existing holdings. Its largest new stake was Vera Therapeutics: 5,265,000 shares worth $227M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $135M trimmed.

  • Avoro Capital Advisors's largest Q1 2024 buy was Vera Therapeutics: 5,265,000 shares worth $227M.
  • Avoro Capital Advisors added most to Arrowhead Research in Q1 2024, an estimated $238M increase.
  • Avoro Capital Advisors's biggest Q1 2024 reduction was Alnylam Pharmaceuticals, cutting an estimated $135M.
  • Avoro Capital Advisors fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $287M.
  • Avoro Capital Advisors's ten largest holdings make up 59% of its $8.57B portfolio in Q1 2024.
  • Avoro Capital Advisors opened 11 new positions and closed 7 in Q1 2024.
  • Avoro Capital Advisors's portfolio value rose 18% quarter-over-quarter to $8.57B.

Based on Avoro Capital Advisors's 13F filing for Q1 2024, filed 15 May 2024.